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Autosomal dominant Alport syndrome caused by a COL4A3 renal failure, often accompanied by high-tone sensori-
splice site mutation. neural deafness and/or ocular abnormalities [3]. Electron
Background. Alport syndrome (AS) is a clinically and genet- microscopy findings include irregular thinning, thick-ically heterogeneous renal disorder, predominantly affecting
ening, and multilamellation of the glomerular basementthe type IV collagen a3/a4/a5 network of the glomerular base-
membrane (GBM). The biochemical defect is located inment membrane (GBM). AS can be caused by mutations in
any of the three genes encoding these type IV collagen chains. the type IV collagen a3/a4/a5 network, which is the main
The majority of AS families (85%) are X-linked (XL-AS) structural component of the GBM. In at least half of the
involving mutations in the COL4A5 gene. Mutations in the
AS patients, this network is absent, as demonstrated byCOL4A3 and COL4A4 genes cause autosomal recessive AS
immunohistochemistry with a(IV)-chain specific anti-(AR-AS), accounting for approximately 14% of the cases. Re-
cently, autosomal dominant AS (AD-AS) was linked to the bodies [4]. In the epidermal basement membrane, the
COL4A3/COL4A4 locus in a large family. a5 chain is also part of the type IV collagen network,
Methods. COL4A3 and COL4A4 cDNAs were generated which can be used to monitor the biochemical effects ofby nested reverse transcription-polymerase chain reaction and
mutations in COL4A5 by immunohistochemistry on skinwere analyzed by DNA sequence analysis. Denaturating high-
biopsy specimens [2, 5].performance liquid chromatography (DHPLC) was used for
mutation and segregation analysis at the genomic DNA level. Genetically, AS is complex. Three modes of inheri-
Results. In the AD-AS family, a splice site mutation re- tance are known, and a large number of mutations have
sulting in skipping of exon 21 of the COL4A3 gene was de-
already been identified in the underlying type IV colla-tected. The mutation does not alter the reading frame and is
gen genes in AS patients. In general, every family has apredicted to result in a COL4A3 chain with an internal deletion.
Conclusion. As the NC domain is intact, this chain may unique mutation. The X-linked dominant form (XL-AS;
be incorporated and distort the collagen triple helix, thereby approximately 85%), caused by mutations in the
causing the dominant effect of the mutation. The finding of a
COL4A5 gene (Xq22-25), predominates, followed by thespecific COL4A3 mutation in AD-AS completes the spectrum
autosomal recessive form (AR-AS; approximately 14%),of type IV collagen mutations in all genetic forms of AS.
caused by mutations in COL4A3 or COL4A4 genes
(2q35-37) [1]. Recently, autosomal dominant AS (AD-
AS; approximately 1%) was linked to the COL4A3/Alport syndrome (AS) is a hereditary glomerulone-
COL4A4 locus in a large family from Northern Irelandphritis with a heterogeneous clinical expression [1, 2].
[6]. The AS patients in this family were mildly affectedThe clinical diagnosis AS is based on a positive family
with only moderately impaired renal function and nohistory of hematuria, proteinuria, or progressive chronic
hearing loss, except for the index patient who reached
end-stage renal disease (ESRD) at an age of 35 yearsKey words: glomerular basement membrane, type IV collagen, exon
skipping, genotype-phenotype correlation, compound heterozygosity. and his father, who also suffered from renal failure. In
general, AD-AS families have a relatively mild pheno-
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Fig. 1. Pedigree of the autosomal dominant Alport syndrome (AD-AS) family indicating heterozygosity for the splice site mutation and the
presence of the nonpathogenic mutation. Heterozygotes for the splice site mutation (COL4A4/exon 21; G . A) are indicated by A/G, whereas
homozygotes for the normal allele are indicated by G/G. Carriers of the nonpathogenic Leu . Pro mutation are indicated by Leu/Pro, while
noncarriers are indicated by Leu/Leu. CC indicates the creatinine clearance (mL/min), and P indicates the 24-hour urinary protein value in grams
(g). The arrow indicates the index patient.
COL4A3 and COL4A4 genes of patients from the AD- Amplification of DNA fragments
AS family using denaturating high-performance liquid Blood samples were collected from family members and
chromatography (DHPLC) and sequence analysis. nonaffected controls. Genomic DNA was isolated by a
salting-out procedure [9]. RNA was isolated from periph-
eral blood lymphocytes (PBLs) or Epstein-Barr virusMETHODS
(EBV)-transformed PBL from affected and normal indi-
Family history viduals using RNAzol [10]. DNA fragments were gener-
In a Caucasian AD-AS family from Northern Ireland, ated by reverse transcription-polymerase chain reaction
male and female patients had only mild features of AS, (RT-PCR) as described before [11, 12]. Oligonucleotides
except for the index patient and his father. The index were designed to amplify COL4A3 and COL4A4 cDNA
patient (III:2) suffered from hematuria, proteinuria, and by multiple overlapping cDNA fragments. COL4A3-
mild hearing loss, and reached ESRD at 35 years (Fig. 1) cDNA, derived from PBL-RNA, was amplified by nested
[6]. His father (II:2) had a history of hematuria, protein- PCR in three large and 11 smaller fragments (Table 1).
uria, and hypertension and suffered from renal failure In the first PCR round, three large fragments were gener-
prior to his death. Renal function was only moderately ated, using 100 ng-1 mg cDNA and 50 ng of each oligonu-
impaired in the other affected siblings (Fig. 1) [6], and cleotide in 670 mmol/L Tris-HCl (pH 8.8), 166 mmol/L
audiograms were normal. Familial benign hematuria (NH4)2SO4, 67 mmol/L MgCl2, 1.7 mg/mL bovine serum
(FBH) was excluded by the presence of mild proteinuria albumin (BSA), 100 mmol/L b-mercaptoethanol, 8 to 15
in the affected family members. The diagnosis of AS was mmol dNTP, 5% dimethyl sulfoxide (DMSO), and 1 U
confirmed by electron microscopy of the GBM in four Ampli-Taq DNA-polymerase (Perkin Elmer, Applied
patients. Immunohistochemistry on paraffin-embedded Biosystems Division, Foster City, CA, USA). Samples
renal biopsy specimens did not show abnormalities in were denaturated for five minutes at 958C, before 30
the type IV collagen a3/a4/a5 network [8]. In a previous cycles of 60-second denaturation at 928C, 90-second an-
study, linkage analysis was performed using eight poly- nealing at 53 to 708C, and 60 to 210 seconds elongation
morphic markers across the region 2q35-37, and AD-AS at 728C were applied (Table 1). For the nested PCRs, 5
to 10 mL of first-round PCR product were used insteadwas linked to this region [6].
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Table 1. Oligonucleotide primers used to amplify COL4A3 cDNA sequences
Fragment
Primer sequence[59!39]: Tann telong
Large Small Forward primer (59 position)a Reverse primer (59 position)a Fragment 8C sec
1 AGGAGACGCGGTGGCCTGAGAGC (95) CAGGGATCCAGGGATACCAGGTGG (2198) 2104 bp 57 210
4 ACTCGCCAGGCTCTGAG (132) GGAGGGCCTGGCAAACC (724) 593 bp 56 90
5 GTGTACCAGGATGCAGTG (523) AGGCTCGCCCATTGCTCC (971) 449 bp 50 70
6 GGTCCTCCGGGATTCTTT (753) CTCGTTCCCCTTTACTTCCTATC (1380) 628 bp 56 90
7 GTGAAGATGGCATTAAGGGAC (1132) AGCCAGCTGCGCCTTGTC (1686) 555 bp 56 90
8 CCAGGATTGCCAGGGTTAC (1626) GAACTCCTTGCGTGCCC (2058) 433 bp 56 90
2 GAAAGGATTACCAGGACCTAAAGGC (1889) ATGTCTCCTGCAGTTCCAGGTGGAC (4024) 2136 bp 53 210
9 ACCAAGGTCCTCCAGGG (1942) TCCTTGTTCTCCAGGTGGTC (2573) 632 bp 57 90
10 AAAGGATCACTGGGTTGTCC (2310) TCCAGGAAATCCCATCATC (2855) 546 bp 57 90
11 CCGGGAATTTTAGGGCCACC (2796) CGTTGGTCCCGGTGGTC (3371) 576 bp 56 90
12 AGGGAGAGCCAGGTTAT TC (3319) CTTGAGCACCAGGGTTC (3726) 408 bp 54 90
3 CAGGAAAGCCAGGTCCTCATGGTG (3496) GAGCAGTGCCTTTGGATGTAAGTG (5451) 1956 bp 63 210
13 CAGGGCCACCAGGTCTGC (3832) CTCTCGTTGTCCAGGTTGCA (4494) 663 bp 56 120
14 CAGCTGGATCAGATGGATTGC (4417) ATACCTAAATAACAGCATGTTCTGTC (5252) 836 bp 56 60
Abbreviations are: Tann, annealing temperature; telong, elongation time.
a Mariyama et al [14]
of the cDNA, and 30 cycles were performed with a 60- the denaturating acetonitrile gradient (46 to 62% elution
buffer; 0.1 to 8.1 min) was experimentally determined.second elongation time. For COL4A4, a similar approach
was used (primer sequences available on request). Be-
fore performing DNA sequencing, the length of the PCR RESULTS
fragments was checked using a standard 2% agarose gel.
The entire COL4A3 and COL4A4 cDNA, derived
Exon 21 of COL4A3 was amplified using intron prim-
from mRNA of EBV-transformed PBL, was amplified
ers (Heidet et al, unpublished data) on genomic DNA by nested PCR. Some of the smaller fragments could be
of the entire family (6 affected and 8 nonaffected) and generated by direct PCR of COL4A3 cDNA, performing
10 controls. 30 PCR cycles, but most fragments were generated by
nested PCR. Amplification of COL4A3 cDNA nucleo-DNA sequencing and denaturating high-performance
tides 1132 to 1686 (59-GTGAAGATGG-. . . GCAGCTliquid chromatography
GGCT-39) [14] showed a cDNA fragment of 555 bp in
COL4A3 and COL4A4 cDNA fragments were puri- control individuals, but fragments of 390 and 555 bp in
fied using Qiaquick DNA purification columns (Qiagen, the index patient (data not shown). Both equally intense
Hilden, Germany), and all fragments were sequenced on fragments were sequenced separately. The smallest frag-
an ABI 310 automated sequencer (Applied Biosystems). ment lacked exon 21 of 165 bp (Heidet et al, unpublished
Reaction conditions using BigDye-terminatorse were data); the larger fragment was the normal cDNA frag-
according to a protocol provided by the manufacturer ment (data not shown).
(Applied Biosystems). Exon 21 was amplified on genomic DNA of the index
Denaturating high-performance liquid chromatogra- patient (III:2) and was analyzed by DHPLC for muta-
tions. A heteroduplex peak was observed (Fig. 2 A, B),phy was performed using the Transgenomic WAVEe
and sequence analysis revealed a G to A substitution of(Transgenomic, San Jose, CA, USA) [13]. Heteroduplexes
the last nucleotide of exon 21 (Fig. 2 C, D). Genomicand homoduplexes of DNA fragments are bound to a
DNA of the entire family (6 affected and 8 nonaffectedstationary phase and eluted by a denaturating gradient
adult family members) and 10 controls was tested byat a constant temperature. Heteroduplexes have a lower
DHLPC. All affected individuals carried the mutation,stability and are eluted before homoduplexes, which can
and none of the unaffected, in line with a causativebe detected as different peaks by ultraviolet absorption.
role for this mutation (Fig. 1). No further pathogenicPCR products were denatured at 958C, reannealed at 658C
COL4A3 or COL4A4 mutations were detected in thisfor 10 minutes, and cooled to 48C to generate hetero-
family, except for a Leu-Pro substitution of unclearduplexes. The products were injected by an autosampler
pathogenicity that has been described before (4582T .on the DNA Sept column. The column mobile phase
C; Leu1472Pro) [6, 11].consisted of a mixture of 0.1 mol/L triethylamine acetate
(pH 7.0) with (elution buffer) or without (running buffer)
DISCUSSION25% acetonitrile. The optimal column temperature (618C)
for the fragment was determined using the DHPLC MELT Autosomal dominant Alport syndrome was recently
linked to the COL4A3/COL4A4 locus in a large North-program (http://insertion.stanford.edu/melt.html), whereas
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Fig. 2. Mutation analysis of the COL4A3 gene.
Denaturing high-pressure liquid chromatog-
raphy (HPLC) analysis of (A) the index pa-
tient showing heteroduplex and homoduplex
peaks and (B) a control person showing one
homoduplex peak. Genomic DNA sequencing
of (C) the index patient and (D) a control
person indicated a point mutation in exon 21.
ern Irish family [6]. As the genomic structure was not on a synergistic effect of compound heterozygosity.
However, the possibility of such an effect has been re-known yet and mRNA levels in PBL were sufficiently
high, these genes were analyzed at the cDNA level. A ported in the literature. For example, dystrophic epider-
molysis bullosa (DEB), in itself a neutral glycine substi-strategy for generating multiple overlapping COL4A3
and COL4A4 cDNA fragments by RT-PCR and nested tution in the COL7A1 gene, aggravated the effect of a
dominant glycine substitution in the other copy of thePCRs was applied, and all fragments could be generated,
although the amplification of some of the fragments was COL7A1 gene, leading to a more severe phenotype in
the compound heterozygote [16].critical. In one of the cDNA fragments of the proband
from the AD-AS family, skipping of exon 21 was found. The COL4A3/21 G . A mutation is the first patho-
genic mutation described in AD-AS. Although an aminoDHPLC followed by sequence analysis of genomic DNA
revealed a missense mutation (COL4A3/21 G . A). acid codon appears to be changed (Gly493Ser), the muta-
tion de facto prohibits correct splicing, resulting in theDHPLC analysis is a rapid and highly sensitive method
for mutation detection [15] and was used to study the skipping of exon 21, as found in the RNA derived from
PBL. The skipped exon comprises 165 bp, resulting insegregation of the mutation at the genomic DNA level.
All affected patients carried the splice site mutation. The a mutated chain that lacks 55 amino acids between
Gly438 to Gly493 in the collagenous domain. It is likelyLeu-Pro substitution in exon 48 of COL4A3 on one of
the maternal chromosomes in itself is not pathogenic that the same will happen in the GBM, as the last nucleo-
tide of an exon is important for correct splicing [17, 18].[6, 11], but may have a secondary effect on the mutated
COL4A3 chain. Although the carriers of both the splice Comparable internal, in-frame deletions have been
identified in type I, III, IV, VI, and VII collagen genes,site and the Leu-Pro mutation (III:2,4,6,9,12) appear to
be more severely affected than the carrier (III:3) of only causing several types of Ehlers Danlos syndrome, osteo-
genesis imperfecta, aortic aneurysms, XL-AS, and Beth-the splice site mutation (Fig. 1), the family is too small
and the available clinical data are too limited to speculate lem myopathy [1, 18, 19]. Most COL4A3 and COL4A4
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mutations have been detected in AR-AS [1, 20]. In most ACKNOWLEDGMENT
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APPENDIXin the COL4A4 gene can lead to either no effect at all
or to FBH with thin basement membranes [20, 21]. It Abbreviations used in this article are: AD-AS, autosomal dominant
Alport syndrome; AR-AS, autosomal recessive Alport syndrome; AS,remains to be established what determines whether het-
Alport syndrome; BSA, bovine serum albumin; DEB, dystrophic epi-erozygosity for mutations in the COL4A4 and COL4A3 dermolysis bullosa; DHPLC, denaturing high performance liquid chro-
genes lead to either FBH or AD-AS. matography, DMSO, dimethyl sulfoxide; EBV, Epstein-Barr virus;
ESRD, end-stage renal disease; FBH, familial benign hematuria; GBM,The dominant nature of COL4A3 mutations and the
glomerular basement membrane; PBL, peripheral blood lymphocytes;different clinical manifestations can be explained in sev- PBL-RNA, RNA derived from peripheric blood lymphocytes; PCR,
polymerase chain reaction; XL-AS, X-linked Alport syndrome.eral ways: first, by the integration of the altered collagen
chain in the final network, thereby disturbing normal
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